UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Pursuant to~~June ~~Section~~28, ~~13 OR 15~~2007 (d)Date of ~~The Securities Exchange Act of 1934~~Report)

~~Date of Report~~GAMMACAN INTERNATIONAL, INC. (~~Date~~Exact name of registrant ~~earliest~~as ~~event~~specified ~~reported):~~in ~~November 30,~~its ~~2006~~charter)

GAMMACAN INTERNATIONAL, INC.


Delaware	0-32835	33-0956433
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

~~(Exact name~~39 ofJerusalem ~~registrant~~Street Kiryat asOno ~~specified~~55423 inIsrael (Address ~~its~~of ~~charter~~principal executive offices)

~~Delaware~~011 972 3 7382616 (Registrant’s telephone number, including area code)

(~~State~~ Former name or ~~other~~ ~~jurisdiction~~former ofaddress, ~~incorporation~~if changed since last report.)

0Check the appropriate box below if the Form 8-~~32835~~K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

(Commission File Number)

33-0956433

(IRS Employer Identification No.)

39 Jerusalem St., Kiryat Ono 55423 Israel

(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: 972 3 738 2616

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

-2-


Item 8.01	Other Events.

On June 28, 2007, an officer of the Registrant delivered an investor presentation that included slides attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. The Registrant undertakes no obligations to update, supplement or amend the attached materials as Exhibit 99.1.

Item 9.01	Financial Statement and Exhibits.

(d) Exhibits

Exhibit	Description


99.1	Form of Investor Presentation

~~ITEM 7.01 Regulation FD Disclosure~~ SIGNATURE

On Pursuant ~~November~~to ~~30, 2006, GammaCan International, Inc. made a presentation concerning its results regarding~~ the ~~efficacy~~requirements ~~and safety~~ of ~~IVIG intravenous immunoglobulin in patients with metastatic melanoma at~~ the ~~5th International~~Securities ~~Congress~~Exchange Act of ~~Autoimmunity in Sorrento~~1934, ~~Italy.~~Registrant ~~The~~has ~~materials~~duly ~~utilized~~caused ~~during the presentation are filed as Exhibit 99.1 to, and incorporated by reference in,~~ this report. ~~In accordance with Regulation FD, this current report is being filed~~ to ~~publicly~~be ~~disclose~~signed ~~all~~on ~~information that was provided in~~ its ~~press~~behalf ~~release.~~by ~~This report under Item 7.01 is not deemed an admission as to~~ the ~~materiality~~undersigned ofhereunto ~~any information in this report that is required to be~~duly ~~disclosed solely by Regulation FD~~authorized.

~~ITEM 9.01.~~Dated: ~~Financial~~June ~~Statements~~28, ~~and Exhibits.~~2007

~~(c) Exhibits~~GAMMACAN INTERNATIONAL, INC. By: /s/ Patrick NJ Schnegelsberg Name: Patrick NJ Schnegelsberg Title: Chief Executive Officer

99.1 Presentation Materials.

-3-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GAMMACAN INTERNATIONAL, INC. /s/ Patrick Schnegelsberg Patrick Schnegelsberg, Chief Executive Officer Date: December 12, 2006

Filing Compare · GAMMACAN INTERNATIONAL INC